Home › Rhabdoid Tumor
Rhabdoid Tumor clinical trials recruiting in the U.S.
17 studies for Rhabdoid Tumor are recruiting participants at sites across the United States.
Cities with the most studies
- Washington, DC5 studies
- Houston, TX4 studies
- Mountain View, CA3 studies
- St. Louis, MO3 studies
- Birmingham, AL3 studies
By state
- Alabama3 studies
- California4 studies
- District of Columbia5 studies
- Missouri3 studies
- Tennessee3 studies
- Texas6 studies
Recently updated studies
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Sep 11, 2026 · NCT07087002NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Sep 9, 2026 · NCT07664176HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Aug 6, 2026 · NCT04715191C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated Jun 23, 2026 · NCT07447076Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.